5 September 2016
Better colon cancer outcomes for coffee drinkers?
Many recent studies link the risk of developing colon cancer with an excess energy balance and subsequently increased blood insulin levels. Coffee consumption has been associated with a decreased risk of type 2 diabetes. Combining these insights, the association of coffee intake with cancer recurrence and mortality was examined in stage III colon cancer patients by tracking their diet and lifestyle in great detail.
2 September 2016
Biomarker identifies colon cancer patients who benefit from chemotherapy after surgery
A means of characterizing stage II colon cancers would allow the identification of high-risk patients who need additional treatment after surgery. New approaches evaluating the expression of multiple genes hold promise, but are currently still too complex for clinical practice. In this study, a new biomarker was found, which could identify at-risk patients using currently available clinical-grade diagnostic assays.
31 August 2016
Buttermilk composition influences its anticancer effect
Buttermilk is a rich source of bioactive polar lipids and proteins. The effect of these molecules in cancer management has been known for over 40 years. This study compared the growth modulatory effects of buttermilks with a different composition on a human colon cancer cell line.
24 August 2016
Sleep inducing hormone puts breast cancer cells to rest
It’s pretty easy to connect the dots between a lack of sleep and an increased risk of a deadly car crash. But what about an increased risk of cancer? A 2012 study of 101 women newly diagnosed with breast cancer found that those with inadequate sleep were more likely to have more aggressive tumors. Though the results of this survey were statistically significant, the biological connection between sleep and breast cancer is not well understood. However, a new study may provide an explanation.
10 August 2016
A novel approach to Ewing sarcoma therapy
Ewing sarcoma is an aggressive bone tumor, most often found in adolescents and young adults. In 85% of the cases, the cells contain a genetic defect where parts are exchanged between two chromosomes, resulting in the production of an oncogenic protein. As this protein is not present in normal cells, disrupting its function is an interesting therapeutic strategy. Previous attempts to target this mechanism directly have failed, but a deeper insight has revealed a new indirect method with potential.
8 August 2016
Breast cancer drug also improves survival in advanced soft-tissue sarcoma
Eribulin is currently approved for metastatic breast cancer. Recently, it has also shown activity in patients with progressive soft-tissue sarcomas who were already treated for advanced disease. In this study, its effect was compared to an active control. A positive effect on survival was found, with an acceptable level of side-effects. This drug can thus be considered an additional tool for the treatment of advanced soft-tissue sarcoma and will be investigated more closely.
5 August 2016
New insights in why obese melanoma patients have a poorer prognosis
Obesity is known to affect both the risk of developing cancer and the prognosis when diagnosed, but the mechanisms are still unclear. This study discovered how surrounding fat cells can reprogram cancer cells to become more aggressive, and why the effect is reinforced by obesity. This opens the door for the creation of molecules targeting the involved mechanisms.
5 August 2016
Stem cells screen drugs for kids’ rare tumor
A team at Johns Hopkins University in Baltimore has transformed stem cells into a particularly nasty form of pediatric brain cancer, medulloblastoma. They then used those cells to figure out what drugs might defeat the tumor and found one existing drug, approved for advanced breast cancer, that seemed to be a good candidate.
3 August 2016
A new biomarker to predict chemotherapy sensitivity in breast cancer
While chemotherapy is being offered to about 60% of patients with breast cancer, combined results of 100.000 cases show that it only reduces recurrence and mortality by 20-33%. In addition to new drugs, the search for molecular markers that can guide the choice of breast cancer treatment is ongoing. When investigating the genes involved in cell growth and division, a new marker SPAG5 was identified, which could become both a new therapeutic target in breast cancer and a prognostic marker for chemotherapy sensitivity.
1 August 2016
New tools to find the best treatment considering your values (and budget)
When deciding on a treatment strategy, cost is sometimes the elephant in the room. Patients can be embarrased to bring up the subject to their physician. Doctors feel discussing price might imply that the patient won’t receive the best possible care if their budget is limited. To counter this, different cancer organizations have created tools to guide patients, physicians and policy makers in choosing the best treatment. For the first time, these also include financial considerations.